Nakano, Hiroki
Hamatani, Yasuhiro
Nagai, Toshiyuki
Nakai, Michikazu
Nishimura, Kunihiro
Sumita, Yoko
Ogawa, Hisao
Anzai, Toshihisa
Funding for this research was provided by:
Grant-in-Aid for Young Scientists from the Japan Society for the Promotion of Science (18K08122)
Pfizer Health Research Foundation
Daiwa Securities Health Foundation
Article History
Received: 17 July 2020
Accepted: 11 December 2020
First Online: 13 January 2021
Competing interests
: Hiroki Nakano, None; Yasuhiro Hamatani, None; Toshiyuki Nagai received a JSPS KAKENHI Grant-in-Aid for Scientific Research, research grants from the Takeda Science Foundation, the Japan Cardiovascular Research Foundation, the Japan Foundation for Aging and Health and the Uehara Memorial Foundation, and honoraria from Daiichi Sankyo Co., Ltd.; Michikazu Nakai, None; Kunihiro Nishimura, None; Yoko Sumita, None; Hisao Ogawa received honoraria from Towa Pharmaceutical Co., Ltd, Bristol-Meyers Squibb Co., Ltd, Pfizer Co., Ltd, Toa Eiyo Co., Ltd, Bayer Yakuhin Co., Ltd and Novartis Pharma Co., Ltd; Toshihisa Anzai received a research grant from the Japan Agency for Medical Research and Development, a research grant from Daiichi Sankyo Co., Ltd., scholarship funds from Biotronik Japan Co., Ltd., Medtronic Japan Co., Ltd., Win International Co., Ltd., Medical System Network Co., Ltd., and Hokuyaku Takeyama Holdings, Inc., and honoraria from Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan Co., Ltd., Bayer’s Pharmaceuticals Co., Ltd., and Bristol-Myers Squibb Co., Ltd.